Sharon Grimster (ReNeuron) to be recognised at bioProcessUK conference

13 November 2019: Sharon Grimster of ReNeuron will be awarded the prestigious Peter Dunnill award at the UK BioIndustry Association’s (BIA) 16th bioProcessUK conference in Liverpool later this month.

To view the UK BioIndustry Association’s (BIA) press release please CLICK HERE.

New data show ReNeuron’s lead CTX cell therapy candidate can be
re-programmed into a pluripotent state and differentiated into other cell types

These new cell types can be efficiently expanded as potential cell therapy candidates targeting a broad range of diseases

23 October 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that new data relating to its CTX stem cell platform will be presented today at the 27th Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), a leading scientific conference taking place this week in Barcelona, Spain.

Read more…

Study investigator presents positive efficacy data in ongoing retinal disease clinical trial

14 October 2019: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, is pleased to announce that positive efficacy data were presented during the weekend at the American Academy of Ophthalmology Annual Meeting (AAO) in San Francisco from the Company’s Phase 1/2a clinical trial of its hRPC stem cell therapy in retinitis pigmentosa (RP).

Read more…

To view the presentation please CLICK HERE.

“Clear efficacy signal” in Phase 2a study of hRPC cell therapy in retinitis pigmentosa

02 October 2019: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, is pleased to announce new positive data in the Company’s ongoing Phase 1/2a clinical trial of its human retinal progenitor cell (hRPC) therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP).

Read more…

12 September 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that all resolutions put to shareholders at its Annual General Meeting (“AGM”) held earlier today were duly passed.

Read more…

10 September 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to provide a trading update ahead of the Company’s Annual General Meeting (“AGM”) this Thursday.

Read more…

21 August 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces the appointment of Professor Robert MacLaren, Dr Sally Temple and Dr José-Alain Sahel to its Scientific Advisory Board.

Read more…

14 August 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it is partnering with the University of Cardiff under a new grant-funded collaboration utilising ReNeuron’s exosome-based drug delivery technology platform.

Read more…

2 August 2019: ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy development company, announces that its Annual Report and Accounts for the year ended 31 March 2019 and the Notice of the 2019 Annual General Meeting (“AGM”) have been sent to shareholders and are also available on the Company’s website at www.reneuron.com.

Read more…

A copy of the Annual Report can be found by clicking here

16 July 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that it has expanded its intellectual property estate via the grant of a number of key patents covering its exosome technology platform.

Read more…